This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Excellent Earnings, Tough Audience; Surprises Among the Leaders: Jim Cramer's Best Blogs

Spectra Energy (SP) has become popular, too. This is a natural gas distribution play with a fine yield that doesn't need to do massive equity financings. It's a quiet winner like so many others on the list.

Oh, and there's Vornado (VNO), a growth real estate investment trust that yields almost 3%. This one has been left for dead at various times, and that is ridiculous, because the canny Steve Roth runs it. I would buy it on any weakness, because it has a solid combination of office and retail properties, especially in the rent-rising areas of New York City.

Some of the others are eye-opening, however. Let's take Allergan (AGN). The story of Allergan is a cautionary one -- for all of those who are dumping Gilead (GILD) and Celgene (CELG), that is. In the tumultuous decline from the $120s to the $80s, one after another analyst turned on the Allergan, saying that it had around-the-corner generic competition for a key eye drug, Latisse. It was incredible; no matter what the company did, it couldn't stop the rumor-mongering about the generic competition. It got so ugly that the CEO, David Pyott, whom I have come to know and like very much, came on "Mad Money" when the stock was in the $80s and said that the patent challenge simply wouldn't hold up and that we would soon be hearing from Allergan about new formulations that couldn't be replicated anyway.

[Read: Is China State Company Reform Real or a Ruse?]

Must Read: Jim Cramer: Spotting a Bottom Is No Easy Affair

When it finally filtered out that the challenge would fail, the stock simply never looked back. But boy, was it painful while it was happening.

How about Snap-On (SNA), which is on tonight? This is a company that has a remarkable, unique franchise that provides the best tools to professional mechanics. It is always inventing new tools -- I call it a "stealth technologist" in Get Rich Carefully. There's no competition.

Southwestern (SWN) and Range Resources (RRC) are pure-play natural gas companies that keep finding more gas and are low-cost producers. They are part and parcel with the energy revolution, but they are also rallying under the false hope that they will provide natural gas to nat-gas-starved places. They are strictly local, and Cheniere (LNG), the first plant to export, won't be ready for several years. I know from my colleague Matt Horween that Chesapeake Energy (CHK) is breaking out, too. The group can't be kept down.

After utilities. it is the oil-service business that predominates notably: Schlumberger (SLB), Baker Hughes (BHI), Helmerich & Payne (HP) and Halliburton. (If my fave, Core Laboratories (CLB), were in the S&P 500 you'd see that, too.) Now when you go listen to the commentary of, say, Baker Hughes, it's pretty obvious what is happening: the North American energy revolution. Baker Hughes on its conference call called out the Permian as one of the fastest-growing areas around the world, verifying, again, that Pioneer Natural Resources (PXD) and EOG Resources (EOG) need to be owned.

The rest are pretty darned eclectic, like Allergan and Snap-On. For example, in a real irony, AutoNation (AN) is on the list. Lots of people credit the beginning of the selloff that we've experienced with comments CEO Michael Jackson gave to Squawk Box about how business has fallen off a cliff and that the car companies were dreaming if they thought they could make their numbers.

Well, guess what? The weather got good, and those inventories cleaned up real fast, and now it's on the 52-week high list, no doubt on the backs of short-sellers who listened to Jackson on television. Oh well, at least he told you on the call that things had gotten better.

One of my absolute favorite companies is and always has been Kimberly-Clark (KMB). The company is never satisfied, always trying to boost the dividend or restructure, and it is willing to sacrifice sales on the altar of profit margins as it did when it ceded the Western Europe diaper market to Procter & Gamble (PG) not that long ago. This company is spinning off its healthcare division, and that has caused me to re-recommend it with a fervor to fill the void of analysts who don't care for it. I think it can inch up to $120 over time, but the dividend protection up there will be meager. No matter, the pieces of the company are worth more than the whole.

I have always like Ball (BLL) ever since it got rid of the Ball jar business and became much more of a high-tech company, particularly in aerospace. It maintains a can business that I think, if spun off, would send the stock much higher. Perhaps that's why it is running?

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Our Tweets

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs